- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
Home
Ubiquitin
E3 ligase Ligand chemical
-
TNF-alpha inhibitor
-
E3 Ligase inhibitor
-
VEGFR inhibitor
-
Caspase activator
-
Apoptosis related activator
Lenalidomide
僅限科研使用
Lenalidomide
別名: CC-5013 中文名稱：來那度胺
Lenalidomide是一種TNF-α分泌抑制劑，在PBMCs中IC50為13 nM。Lenalidomide是 ubiquitin E3 ligase cereblon (CRBN) 的配體，它通過CRBN-CRL4泛素連接酶引起兩個淋巴樣轉錄因子IKZF1和IKZF3的選擇性泛素化和降解。Lenalidomide 可促進 cleaved caspase-3 的表達、抑制 VEGF 的表達并誘導凋亡。
Lenalidomide Chemical Structure
CAS: 191732-72-6
產(chǎn)品質(zhì)控
批次：
純度：
99.99%
99.99
Lenalidomide相關產(chǎn)品
| 相關產(chǎn)品 | Iberdomide (CC220) | 點擊展開 |
|---|---|---|
| 相關化合物庫 | 激酶抑制劑庫 FDA藥物庫 天然產(chǎn)物庫 已知活性藥物庫-I 高選擇性抑制劑庫 | 點擊展開 |
細胞實驗數(shù)據(jù)示例
| 細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
|---|---|---|---|---|---|
| DF15 | Function assay | 0.1 to 10 uM | 5 hrs | Induction of cereblon-mediated aiolos degradation in human DF15 cells at 0.1 to 10 uM after 5 hrs by immunoblot analysis | 28425720 |
| OPM2 | Function assay | 0.1 to 10 uM | 5 hrs | Induction of cereblon-mediated aiolos degradation in human OPM2 cells at 0.1 to 10 uM after 5 hrs by immunoblot analysis | 28425720 |
| DF15 | Function assay | 0.1 to 10 uM | 5 hrs | Induction of cereblon-mediated ikaros degradation in human DF15 cells at 0.1 to 10 uM after 5 hrs by immunoblot analysis | 28425720 |
| OPM2 | Function assay | 0.1 to 10 uM | 5 hrs | Induction of cereblon-mediated ikaros degradation in human OPM2 cells at 0.1 to 10 uM after 5 hrs by immunoblot analysis | 28425720 |
| EC9706 | Antiproliferative assay | 150 ug/mL | 48 hrs | Antiproliferative activity against human EC9706 cells at 150 ug/mL after 48 hrs by CCK-8 assay | 28757066 |
| DF15 | Function assay | 4 hrs | Induction of CRL4/CRBN ubiquitin ligase-mediated aiolos degradation in human DF15 cells expressing pLOC-ePL-tagged aiolos after 4 hrs by luminescence based beta-galactosidase enzyme fragmentation complementation assay, EC50 = 0.053 μM. | 28358507 | |
| DF15 | Function assay | 4 hrs | Induction of cereblon-mediated ikaros degradation in human DF15 cells expressing ePL-tagged ikaros after 4 hrs by luminometric analysis, EC50 = 0.067 μM. | 28425720 | |
| DF15 | Function assay | 4 hrs | Induction of cereblon-mediated aiolos degradation in human DF15 cells expressing ePL-tagged aiolos after 4 hrs by luminometric analysis, EC50 = 0.087 μM. | 28425720 | |
| T-cells | Function assay | 2 to 3 days | Inhibition of IL-2 production in human T cells measured after 2 to 3 days by ELISA, EC50 = 0.15 μM. | 23168019 | |
| NAMALWA | Antiproliferative assay | 72 hrs | Antiproliferative activity against human NAMALWA cells assessed as inhibition of [3H]thymidine incorporation after 72 hrs by scintillation counting, IC50 = 0.36 μM. | 23168019 | |
| CD34+ progenitor cells | Function assay | 14 days | Decrease in erythroid differentiation of CD34+ progenitor cells from myelodysplastic syndrome del(5q) patient assessed as CD36 expression after 14 days | 17576924 | |
| CD34+ progenitor cells | Function assay | 14 days | Decrease in myeloid differentiation of CD34+ progenitor cells from myelodysplastic syndrome del(5q) patient assessed as CD33 expression after 14 days | 17576924 | |
| CD34+ progenitor cells | Function assay | 14 days | Decrease in erythroid differentiation of CD34+ progenitor cells from myelodysplastic syndrome del(5q) patient assessed as glycophorin A expression after 14 days | 17576924 | |
| CD34+ progenitor cells | Growth inhibition assay | 14 days | Inhibition of cell proliferation of CD34+ progenitor cells from myelodysplastic syndrome del(5q) patient after 14 days | 17576924 | |
| CD34+ progenitor cells | Growth inhibition assay | 14 days | Growth inhibition of CD34+ progenitor cells from non-del(5q) myelodysplastic syndrome patient after 14 days | 17576924 | |
| A2780 | Growth Inhibition Assay | IC50=35.3601 μM | SANGER | ||
| ECC10 | Growth Inhibition Assay | IC50=34.7443 μM | SANGER | ||
| NKM-1 | Growth Inhibition Assay | IC50=32.9568 μM | SANGER | ||
| NCI-H526 | Growth Inhibition Assay | IC50=32.683 μM | SANGER | ||
| SK-OV-3 | Growth Inhibition Assay | IC50=31.6755 μM | SANGER | ||
| C8166 | Growth Inhibition Assay | IC50=31.2274 μM | SANGER | ||
| JEG-3 | Growth Inhibition Assay | IC50=31.1614 μM | SANGER | ||
| KYSE-520 | Growth Inhibition Assay | IC50=30.8839 μM | SANGER | ||
| HCC70 | Growth Inhibition Assay | IC50=30.7346 μM | SANGER | ||
| SW1990 | Growth Inhibition Assay | IC50=30.33 μM | SANGER | ||
| WM-115 | Growth Inhibition Assay | IC50=30.3099 μM | SANGER | ||
| MV-4-11 | Growth Inhibition Assay | IC50=29.7317 μM | SANGER | ||
| ABC-1 | Growth Inhibition Assay | IC50=29.6974 μM | SANGER | ||
| HDLM-2 | Growth Inhibition Assay | IC50=28.2026 μM | SANGER | ||
| HCC2218 | Growth Inhibition Assay | IC50=25.5407 μM | SANGER | ||
| HuP-T3 | Growth Inhibition Assay | IC50=25.4009 μM | SANGER | ||
| CTV-1 | Growth Inhibition Assay | IC50=25.0149 μM | SANGER | ||
| SBC-1 | Growth Inhibition Assay | IC50=23.8696 μM | SANGER | ||
| ES3 | Growth Inhibition Assay | IC50=22.6963 μM | SANGER | ||
| RS4-11 | Growth Inhibition Assay | IC50=22.1563 μM | SANGER | ||
| MOLT-4 | Growth Inhibition Assay | IC50=20.5759 μM | SANGER | ||
| MSTO-211H | Growth Inhibition Assay | IC50=20.3573 μM | SANGER | ||
| LN-405 | Growth Inhibition Assay | IC50=19.9076 μM | SANGER | ||
| TE-1 | Growth Inhibition Assay | IC50=17.9968 μM | SANGER | ||
| IGROV-1 | Growth Inhibition Assay | IC50=17.783 μM | SANGER | ||
| HSC-4 | Growth Inhibition Assay | IC50=17.6601 μM | SANGER | ||
| EM-2 | Growth Inhibition Assay | IC50=17.143 μM | SANGER | ||
| H9 | Growth Inhibition Assay | IC50=16.626 μM | SANGER | ||
| ACN | Growth Inhibition Assay | IC50=16.5297 μM | SANGER | ||
| SK-MEL-24 | Growth Inhibition Assay | IC50=16.4652 μM | SANGER | ||
| K5 | Growth Inhibition Assay | IC50=16.1486 μM | SANGER | ||
| DEL | Growth Inhibition Assay | IC50=15.499 μM | SANGER | ||
| COLO-684 | Growth Inhibition Assay | IC50=15.3979 μM | SANGER | ||
| PANC-08-13 | Growth Inhibition Assay | IC50=14.9108 μM | SANGER | ||
| HAL-01 | Growth Inhibition Assay | IC50=14.5796 μM | SANGER | ||
| LCLC-103H | Growth Inhibition Assay | IC50=14.4892 μM | SANGER | ||
| SW620 | Growth Inhibition Assay | IC50=14.2473 μM | SANGER | ||
| A2058 | Growth Inhibition Assay | IC50=13.8199 μM | SANGER | ||
| HOP-62 | Growth Inhibition Assay | IC50=13.48 μM | SANGER | ||
| T47D | Growth Inhibition Assay | IC50=13.2099 μM | SANGER | ||
| RPMI-8226 | Growth Inhibition Assay | IC50=12.6241 μM | SANGER | ||
| SK-MEL-28 | Growth Inhibition Assay | IC50=11.9764 μM | SANGER | ||
| KASUMI-1 | Growth Inhibition Assay | IC50=11.571 μM | SANGER | ||
| HCC1806 | Growth Inhibition Assay | IC50=11.4467 μM | SANGER | ||
| HMV-II | Growth Inhibition Assay | IC50=10.0172 μM | SANGER | ||
| BV-173 | Growth Inhibition Assay | IC50=8.67585 μM | SANGER | ||
| SK-NEP-1 | Growth Inhibition Assay | IC50=7.89512 μM | SANGER | ||
| BT-549 | Growth Inhibition Assay | IC50=6.21849 μM | SANGER | ||
| EoL-1-cell | Growth Inhibition Assay | IC50=4.10515 μM | SANGER | ||
| JAR | Growth Inhibition Assay | IC50=2.97001 μM | SANGER | ||
| L-363 | Growth Inhibition Assay | IC50=2.92212 μM | SANGER | ||
| LB771-HNC | Growth Inhibition Assay | IC50=2.15038 μM | SANGER | ||
| KY821 | Growth Inhibition Assay | IC50=35.7681 μM | SANGER | ||
| MKN1 | Growth Inhibition Assay | IC50=36.2137 μM | SANGER | ||
| EKVX | Growth Inhibition Assay | IC50=37.4212 μM | SANGER | ||
| EW-16 | Growth Inhibition Assay | IC50=38.3885 μM | SANGER | ||
| CTB-1 | Growth Inhibition Assay | IC50=39.7789 μM | SANGER | ||
| COR-L105 | Growth Inhibition Assay | IC50=40.4746 μM | SANGER | ||
| NCI-SNU-5 | Growth Inhibition Assay | IC50=41.2069 μM | SANGER | ||
| Mewo | Growth Inhibition Assay | IC50=41.9871 μM | SANGER | ||
| BCPAP | Growth Inhibition Assay | IC50=43.7917 μM | SANGER | ||
| KARPAS-45 | Growth Inhibition Assay | IC50=44.2776 μM | SANGER | ||
| NCI-H1693 | Growth Inhibition Assay | IC50=46.6986 μM | SANGER | ||
| H-EMC-SS | Growth Inhibition Assay | IC50=48.3224 μM | SANGER | ||
| 697 | Growth Inhibition Assay | IC50=50.3545 μM | SANGER | ||
| KP-N-YS | Growth Inhibition Assay | IC50=52.3142 μM | SANGER | ||
| NCI-H1304 | Growth Inhibition Assay | IC50=52.7024 μM | SANGER | ||
| NOS-1 | Growth Inhibition Assay | IC50=52.8559 μM | SANGER | ||
| NCI-H2342 | Growth Inhibition Assay | IC50=53.0508 μM | SANGER | ||
| KYSE-270 | Growth Inhibition Assay | IC50=53.6364 μM | SANGER | ||
| LU-135 | Growth Inhibition Assay | IC50=55.1853 μM | SANGER | ||
| OE33 | Growth Inhibition Assay | IC50=55.818 μM | SANGER | ||
| ML-2 | Growth Inhibition Assay | IC50=55.9489 μM | SANGER | ||
| KMOE-2 | Growth Inhibition Assay | IC50=56.2893 μM | SANGER | ||
| Daoy | Growth Inhibition Assay | IC50=56.3204 μM | SANGER | ||
| KNS-62 | Growth Inhibition Assay | IC50=57.0142 μM | SANGER | ||
| NBsusSR | Growth Inhibition Assay | IC50=57.5705 μM | SANGER | ||
| UACC-257 | Growth Inhibition Assay | IC50=58.6264 μM | SANGER | ||
| LU-139 | Growth Inhibition Assay | IC50=58.826 μM | SANGER | ||
| CAL-85-1 | Growth Inhibition Assay | IC50=58.8643 μM | SANGER | ||
| NCI-H720 | Growth Inhibition Assay | IC50=58.8942 μM | SANGER | ||
| MLMA | Growth Inhibition Assay | IC50=59.091 μM | SANGER | ||
| A3-KAW | Growth Inhibition Assay | IC50=59.2809 μM | SANGER | ||
| Ramos-2G6-4C10 | Growth Inhibition Assay | IC50=59.6287 μM | SANGER | ||
| A388 | Growth Inhibition Assay | IC50=60.449 μM | SANGER | ||
| LAMA-84 | Growth Inhibition Assay | IC50=60.9905 μM | SANGER | ||
| GCT | Growth Inhibition Assay | IC50=61.0786 μM | SANGER | ||
| K-562 | Growth Inhibition Assay | IC50=61.5333 μM | SANGER | ||
| NCI-H1666 | Growth Inhibition Assay | IC50=61.875 μM | SANGER | ||
| NCI-H1993 | Growth Inhibition Assay | IC50=63.4043 μM | SANGER | ||
| NCI-H358 | Growth Inhibition Assay | IC50=65.0121 μM | SANGER | ||
| NB6 | Growth Inhibition Assay | IC50=65.988 μM | SANGER | ||
| HCE-T | Growth Inhibition Assay | IC50=67.0798 μM | SANGER | ||
| DOK | Growth Inhibition Assay | IC50=67.4948 μM | SANGER | ||
| HT-1376 | Growth Inhibition Assay | IC50=69.8314 μM | SANGER | ||
| NEC8 | Growth Inhibition Assay | IC50=70.1243 μM | SANGER | ||
| G-402 | Growth Inhibition Assay | IC50=70.9395 μM | SANGER | ||
| GR-ST | Growth Inhibition Assay | IC50=71.172 μM | SANGER | ||
| QIMR-WIL | Growth Inhibition Assay | IC50=71.4434 μM | SANGER | ||
| CHP-212 | Growth Inhibition Assay | IC50=71.965 μM | SANGER | ||
| KU812 | Growth Inhibition Assay | IC50=72.9702 μM | SANGER | ||
| Becker | Growth Inhibition Assay | IC50=73.1489 μM | SANGER | ||
| ChaGo-K-1 | Growth Inhibition Assay | IC50=74.7486 μM | SANGER | ||
| A498 | Growth Inhibition Assay | IC50=74.9308 μM | SANGER | ||
| NCI-H69 | Growth Inhibition Assay | IC50=75.7663 μM | SANGER | ||
| NCI-H209 | Growth Inhibition Assay | IC50=78.6147 μM | SANGER | ||
| CAL-33 | Growth Inhibition Assay | IC50=78.9939 μM | SANGER | ||
| COLO-680N | Growth Inhibition Assay | IC50=79.1007 μM | SANGER | ||
| D-283MED | Growth Inhibition Assay | IC50=79.812 μM | SANGER | ||
| ATN-1 | Growth Inhibition Assay | IC50=81.1187 μM | SANGER | ||
| NCI-N87 | Growth Inhibition Assay | IC50=81.7296 μM | SANGER | ||
| MHH-NB-11 | Growth Inhibition Assay | IC50=81.8849 μM | SANGER | ||
| HEL | Growth Inhibition Assay | IC50=82.4134 μM | SANGER | ||
| NB69 | Growth Inhibition Assay | IC50=83.0033 μM | SANGER | ||
| MPP-89 | Growth Inhibition Assay | IC50=83.2575 μM | SANGER | ||
| COLO-829 | Growth Inhibition Assay | IC50=85.4912 μM | SANGER | ||
| ONS-76 | Growth Inhibition Assay | IC50=85.7908 μM | SANGER | ||
| EW-3 | Growth Inhibition Assay | IC50=86.2032 μM | SANGER | ||
| EW-11 | Growth Inhibition Assay | IC50=86.4336 μM | SANGER | ||
| SW900 | Growth Inhibition Assay | IC50=87.2053 μM | SANGER | ||
| MOLT-13 | Growth Inhibition Assay | IC50=87.2243 μM | SANGER | ||
| HuP-T4 | Growth Inhibition Assay | IC50=91.0405 μM | SANGER | ||
| HCC1419 | Growth Inhibition Assay | IC50=91.6374 μM | SANGER | ||
| CAL-72 | Growth Inhibition Assay | IC50=92.0219 μM | SANGER | ||
| Mo-T | Growth Inhibition Assay | IC50=92.7697 μM | SANGER | ||
| OC-314 | Growth Inhibition Assay | IC50=92.8821 μM | SANGER | ||
| BHT-101 | Growth Inhibition Assay | IC50=93.1 μM | SANGER | ||
| EW-18 | Growth Inhibition Assay | IC50=93.8462 μM | SANGER | ||
| TE-12 | Growth Inhibition Assay | IC50=94.3055 μM | SANGER | ||
| MDA-MB-361 | Growth Inhibition Assay | IC50=96.0516 μM | SANGER | ||
| 點擊查看更多細胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | Lenalidomide是一種TNF-α分泌抑制劑，在PBMCs中IC50為13 nM。Lenalidomide是 ubiquitin E3 ligase cereblon (CRBN) 的配體，它通過CRBN-CRL4泛素連接酶引起兩個淋巴樣轉錄因子IKZF1和IKZF3的選擇性泛素化和降解。Lenalidomide 可促進 cleaved caspase-3 的表達、抑制 VEGF 的表達并誘導凋亡。 | ||||||
|---|---|---|---|---|---|---|---|
| 靶點 |
|
| 體外研究(In Vitro) | ||||
| 體外研究活性 | CC-5013強誘導IL-2和sIL-2R產(chǎn)量。CC-5013作用于T細胞，誘導CD28的酪氨酸磷酸化，隨后下調(diào)NF-κB的激活。[2] Lenalidomide和Pomalidomide作用于表達與Thalidomide結合野生型CRBN的，而不是Thalidomide結合缺陷型CRBN(YW/AA)的HEK293 T細胞，抑制CRBN自體泛素化。KMS12多發(fā)性骨髓瘤細胞中，CRBN野生型蛋白而不是CRBN(YW/AA) 突變型蛋白的過表達, 放大Pomalidomide調(diào)節(jié)的c-myc和IRF4表達降低和p21(WAF-1) 表達增高。H929 多發(fā)性骨髓瘤細胞系中長期抗Lenalidomide 的選擇性與CRBN降低相關,然而抗Pomalidomide和 Lenalidomide的DF15R多發(fā)性骨髓瘤 中, 檢測不到CRBN蛋白。[3] Lenalidomide通過下調(diào)腫瘤細胞抑制性分子表達而抑制缺陷發(fā)生。Lenalidomide防止腫瘤誘導的T細胞裂解功能障礙發(fā)生。Lenalidomide 作用于T細胞，抑制慢性淋巴細胞性白血病（CLL）細胞誘導的T細胞肌動蛋白突觸功能受損, 且下調(diào)CLL抑制配體及其他受體的表達。Lenalidomide 作用于FL, DLBCL, HL, MM, SCC,和 OC，抑制腫瘤誘導的免疫抑制，且作用于所有檢測的腫瘤細胞時,下調(diào)免疫抑制配體表達。[4] |
|||
|---|---|---|---|---|
| 細胞實驗 | 細胞系 | 良性或惡性 B (CLL)細胞, RPMI8226 MM 細胞 | ||
| 濃度 | 1 μM或5 nM | |||
| 孵育時間 | 24小時 | |||
| 方法 | 使用CellTracker Blue CMAC對良性或惡性B (CLL)細胞(2 × 106)進行染色， 然后使用2 μg/mL金黃色葡萄球菌超抗原(sAg) (SEA 和 SEB) 在37oC下進行脈沖處理30分鐘。B細胞和等量T細胞(從原代共培養(yǎng)中純化的)按200 × g轉速離心5分鐘，然后與CD8+ T 細胞在37oC下溫育10分鐘，或者與 CD3+ T細胞溫育20分鐘。使用細胞收集器使細胞轉移到顯微鏡載玻片上，然后在室溫下和3% 溶于PBS的甲醛混合15分鐘。在完全培養(yǎng)基中加入終濃度為1 μM的Lenalidomide。對照組則使用DMSO處理細胞。 |
|||
| 實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
| Western blot | MDM2 / p-MDM2 / p-p53 / p53 phospho-IKKβ / IKKβ |
|
22525275 | |
| Growth inhibition assay | Cell viability |
|
22698399 | |
| 體內(nèi)研究(In Vivo) | ||
| 體內(nèi)研究活性 | 口服處理Lenalidomide，顯著抑制bFGF誘導的血管生成，這種作用存在劑量依賴性。Lenalidomide 顯著降低血管面積百分數(shù)，從對照組的5.16%降低到實驗組的2.58（50 mg/kg劑量處理）和 1.69（250 mg/kg 劑量處理）。 Lenalidomide 顯著降低全部MVL，從對照組的21.07降低到實驗組的8.11（50 mg/kg劑量處理）和1.90（250 mg/kg劑量處理）。[5] |
|
|---|---|---|
| 動物實驗 | Animal Models | 攜帶HUVECs細胞的成年雄性Sprague–Dawley大鼠 |
| Dosages | 50 mg/kg和250 mg/kg | |
| Administration | 腹腔注射 | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06177028 | Not yet recruiting | Cognitive Impairment Mild|Cognitive Dysfunction|Amyloid Plaque|Neurodegenerative Disease Hereditary|Inflammation Brain |
St. Joseph''s Hospital and Medical Center Phoenix|Texas Tech University |
January 2 2024 | Phase 2 |
| NCT06149286 | Recruiting | Relapsed/Refractory Follicular Lymphoma|Marginal Zone Lymphoma (MZL) |
Regeneron Pharmaceuticals |
December 28 2023 | Phase 3 |
| NCT06299553 | Recruiting | DLBCL - Diffuse Large B Cell Lymphoma |
Incyte Biosciences Italy S.r.l |
December 4 2023 | -- |
化學信息&溶解度
| 分子量 | 259.26 | 分子式 | C13H13N3O3 |
| CAS號 | 191732-72-6 | SDF | Download Lenalidomide SDF |
| Smiles | C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N | ||
| 儲存條件(自收到貨起) | |||
|
體外溶解度 |
DMSO : 52 mg/mL ( (200.57 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
|
體內(nèi)溶解度 現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 | ||||
實驗計算
動物體內(nèi)配方計算器（澄清溶液）
第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）
mg/kg
g
μL
只
第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術支持
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題，請給我們留言。
* 必填項
常見問題及建議解決方法
問題 1:
What is the formulation for mouse injection(i.p.)?
回答：
This paper has the information you need: http://link.springer.com/article/10.1208/s12248-012-9401-2. Add lenalidomide to the appropriate volume of sterile phosphate-buffered saline (PBS) containing 1% hydrochloric acid (HCl). the pH of this preparation was adjusted to 7.0–7.6 using sodium hydroxide and sterile filtered using a 0.22 μm Steriflip filter.
問題 2:
what is the procedure to resuspend this compound？
回答：
You can resuspend this compund by DMSO, the solubility is about 52 mg/mL (200.57 mM). For in vivo study, you can prepare the working solution with the vehicle of: 30% PEG400/0.5% Tween80/5% propylene glycol for oral administration.
Tags: buy Lenalidomide | Lenalidomide supplier | purchase Lenalidomide | Lenalidomide cost | Lenalidomide manufacturer | order Lenalidomide | Lenalidomide distributor
